{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:56:08Z","timestamp":1790618168255,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174059"],"award-info":[{"award-number":["82174059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2022SF-123"],"award-info":[{"award-number":["2022SF-123"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Young and Middle-Aged Scientific and Technological Talents of Shaanxi Administration of Traditional Chinese Medicine","award":["2023-ZQNY-004"],"award-info":[{"award-number":["2023-ZQNY-004"]}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2022-SLRH-YQ-001"],"award-info":[{"award-number":["2022-SLRH-YQ-001"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Planning Project of Shenzen Municipality, China\u4e2d\u56fd\u795e\u7985\u5e02\u79d1\u6280\u89c4\u5212\u9879\u76ee","award":["JCYJ20250604184258076"],"award-info":[{"award-number":["JCYJ20250604184258076"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC), a chronic-relapsing inflammatory disease with rising prevalence worldwide, is primarily driven by intestinal epithelial barrier dysfunction resulting from gut microbial dysbiosis and metabolic disturbances. Daikenchuto (DKT), a traditional Chinese medicine formulation, is commonly used for digestive disorders. Although DKT has demonstrated therapeutic potential for gut inflammation by modulating gut microbiota, its therapeutic effects on chronic ulcerative colitis (CUC) and the related mechanisms remain elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The main components of DKT were tentatively identified using ultra-performance liquid chromatography-quadrupole-time of flight-mass spectrometry (UPLC-Q-TOF-MS), and the therapeutic effects of DKT were evaluated in the mouse models of acute colitis (AC) and CUC induced using dextran sulfate sodium. The models were validated based on alterations in the disease activity index (DAI), colonic inflammatory status, and intestinal barrier integrity. The impact of DKT on the dysbiosis of gut microbiota was evaluated using the\n                      <jats:italic>16S rRNA<\/jats:italic>\n                      gene and metagenomic sequencing. Targeted metabolomics was conducted to quantify shifts in short-chain fatty acids and tryptophan (Trp) metabolites. To further elucidate the underlying mechanisms of DKT, key pathways were analyzed using Western blotting, immunohistochemistry, and real-time quantitative polymerase chain reaction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The principal constituents of DKT were tentatively identified. DKT administration significantly alleviated the symptoms of AC and CUC, reduced inflammation, and maintained intestinal barrier function. Furthermore, DKT modulated the structure and abundance of gut microbiota. Metagenomic sequencing analysis demonstrated that DKT significantly enriched the relative abundance of\n                      <jats:italic>Ligilactobacillus murinus<\/jats:italic>\n                      ,\n                      <jats:italic>Lactobacillus taiwanensis<\/jats:italic>\n                      , and\n                      <jats:italic>Lactobacillus johnsonii<\/jats:italic>\n                      . Moreover, Trp metabolism and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathways might be the therapeutic mechanisms of DKT. Targeted metabolomics confirmed that Trp\/indole was the major pathway during the therapeutic process of DKT on CUC. Further mechanistic studies demonstrated that activation of the aryl hydrocarbon receptor (AhR) signaling enhanced proliferation in the colonic crypts by stimulating IL-22 secretion and promoting STAT3 phosphorylation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DKT alleviated AC and CUC in mouse models by modulating gut microbiota, restoring Trp metabolism, and activating the AhR\/IL-22\/STAT3 signaling pathway. These findings provide a basis for the clinical application of DKT in UC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01358-4","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:41:03Z","timestamp":1773657663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Daikenchuto ameliorates dextran sulfate sodium-induced acute and chronic ulcerative colitis by regulating gut microbiota-derived indoles to activate AhR signaling"],"prefix":"10.1186","volume":"21","author":[{"given":"Rui","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menggai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanghui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106146","volume":"178","author":"H Luo","year":"2022","unstructured":"Luo H, Cao G, Luo C, Tan D, Vong CT, Xu Y, et al. Emerging pharmacotherapy for inflammatory bowel diseases. Pharmacol Res. 2022;178:106146.","journal-title":"Pharmacol Res"},{"issue":"30","key":"1358_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado7438","volume":"10","author":"L Huang","year":"2024","unstructured":"Huang L, Hu W, Huang LQ, Zhou QX, Song ZY, Tao HY, et al. Two-birds-one-stone\" oral nanotherapeutic designed to target intestinal integrins and regulate redox homeostasis for UC treatment. Sci Adv. 2024;10(30):eado7438.","journal-title":"Sci Adv"},{"issue":"6","key":"1358_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.","journal-title":"Gastroenterology"},{"issue":"10401","key":"1358_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571\u201384.","journal-title":"Lancet"},{"issue":"8","key":"1358_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jama.2023.23814","volume":"331","author":"R Voelker","year":"2024","unstructured":"Voelker R. What is ulcerative colitis? JAMA. 2024;331(8):716.","journal-title":"JAMA"},{"issue":"6","key":"1358_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489\u2013526.","journal-title":"J Gastroenterol"},{"issue":"12","key":"1358_CR7","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1007\/s10620-023-08122-w","volume":"68","author":"KA Dunleavy","year":"2023","unstructured":"Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Dig Dis Sci. 2023;68(12):4306\u201320.","journal-title":"Dig Dis Sci"},{"issue":"7351","key":"1358_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10208","volume":"474","author":"KJ Maloy","year":"2011","unstructured":"Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474(7351):298\u2013306.","journal-title":"Nature"},{"key":"1358_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.643973","volume":"8","author":"K Sommer","year":"2021","unstructured":"Sommer K, Wiendl M, M\u00fcller TM, Heidbreder K, Voskens C, Neurath MF, et al. Intestinal mucosal wound healing and barrier integrity in IBD-crosstalk and trafficking of cellular players. Front Med (Lausanne). 2021;8:643973.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1358_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103717","volume":"24","author":"Y Qiao","year":"2025","unstructured":"Qiao Y, He C, Xia Y, Ocansey DKW, Mao F. Intestinal mucus barrier: a potential therapeutic target for IBD. Autoimmun Rev. 2025;24(2):103717.","journal-title":"Autoimmun Rev"},{"key":"1358_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2025.123971","volume":"367","author":"W Wang","year":"2025","unstructured":"Wang W, Tu F, Yang Z, Gu M, Wang Y, Gao Z, et al. Pectin\/arabinoxylan dietary polysaccharide microcapsule encapsulated with Clostridium butyricum for targeted delivery in colitis treatment. Carbohydr Polym. 2025;367:123971.","journal-title":"Carbohydr Polym"},{"issue":"6","key":"1358_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27530","volume":"10","author":"T Wang","year":"2024","unstructured":"Wang T, Liu X, Zhang W, Wang J, Wang T, Yue W, et al. Traditional Chinese medicine treats ulcerative colitis by regulating gut microbiota, signaling pathway and cytokine: future novel method option for pharmacotherapy. Heliyon. 2024;10(6):e27530.","journal-title":"Heliyon"},{"issue":"6","key":"1358_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcmgh.2016.06.004","volume":"2","author":"JP Jacobs","year":"2016","unstructured":"Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Ruegger P, et al. A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cell Mol Gastroenterol Hepatol. 2016;2(6):750\u201366.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"1358_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13568-021-01267-9","volume":"11","author":"YH Tang","year":"2021","unstructured":"Tang YH, Liu HC, Song G, Wu TT, Zhao Y, Shi LJ. A case-control study on the association of intestinal flora with ulcerative colitis. AMB Express. 2021;11(1):106.","journal-title":"AMB Express"},{"issue":"1","key":"1358_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/1348-0421.12749","volume":"64","author":"AL Li","year":"2020","unstructured":"Li AL, Ni WW, Zhang QM, Li Y, Zhang X, Wu HY, et al. Effect of cinnamon essential oil on gut microbiota in the mouse model of dextran sodium sulfate-induced colitis. Microbiol Immunol. 2020;64(1):23\u201332.","journal-title":"Microbiol Immunol"},{"issue":"11","key":"1358_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gut.2003.037747","volume":"53","author":"W Kruis","year":"2004","unstructured":"Kruis W, Fric P, Pokrotnieks J, Luk\u00e1s M, Fixa B, Kasc\u00e1k M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53(11):1617\u201323.","journal-title":"Gut"},{"issue":"2","key":"1358_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/gut.2004.044834","volume":"54","author":"E Furrie","year":"2005","unstructured":"Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O\u2019Neil DA, et al. Synbiotic therapy (Bifidobacterium longum\/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54(2):242\u20139.","journal-title":"Gut"},{"issue":"10075","key":"1358_CR18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","volume":"389","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218\u201328.","journal-title":"Lancet"},{"issue":"5","key":"1358_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s13238-018-0549-0","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein & Cell. 2018;9(5):416\u201331.","journal-title":"Protein & Cell"},{"key":"1358_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108605","volume":"256","author":"LM Williams","year":"2024","unstructured":"Williams LM, Cao S. Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches. Pharmacol Ther. 2024;256:108605.","journal-title":"Pharmacol Ther"},{"issue":"7423","key":"1358_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature11465","volume":"491","author":"SI Grivennikov","year":"2012","unstructured":"Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23\/IL-17-mediated tumour growth. Nature. 2012;491(7423):254\u20138.","journal-title":"Nature"},{"issue":"5","key":"1358_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202000461","volume":"65","author":"X Li","year":"2021","unstructured":"Li X, Zhang ZH, Zabed HM, Yun J, Zhang G, Qi X. An insight into the roles of dietary tryptophan and its metabolites in intestinal inflammation and inflammatory bowel disease. Mol Nutr Food Res. 2021;65(5):e2000461.","journal-title":"Mol Nutr Food Res"},{"key":"1358_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1279172","volume":"13","author":"JJ Hou","year":"2023","unstructured":"Hou JJ, Ma AH, Qin YH. Activation of the aryl hydrocarbon receptor in inflammatory bowel disease: insights from gut microbiota. Front Cell Infect Microbiol. 2023;13:1279172.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"1358_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jnutbio.2009.01.019","volume":"21","author":"CJ Kim","year":"2010","unstructured":"Kim CJ, Kovacs-Nolan JA, Yang C, Archbold T, Fan MZ, Mine Y. L-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. J Nutr Biochem. 2010;21(6):468\u201375.","journal-title":"J Nutr Biochem"},{"key":"1358_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jnutbio.2016.12.019","volume":"42","author":"J Islam","year":"2017","unstructured":"Islam J, Sato S, Watanabe K, Watanabe T, Ardiansyah Hirahara K, et al. Dietary tryptophan alleviates dextran sodium sulfate-induced colitis through aryl hydrocarbon receptor in mice. J Nutr Biochem. 2017;42:43\u201350.","journal-title":"J Nutr Biochem"},{"issue":"7","key":"1358_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3748\/wjg.v23.i7.1180","volume":"23","author":"L Zheng","year":"2017","unstructured":"Zheng L, Zhang YL, Dai YC, Chen X, Chen DL, Dai YT, et al. Jianpi qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-\u03baB activation. World J Gastroenterol. 2017;23(7):1180\u20138.","journal-title":"World J Gastroenterol"},{"key":"1358_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154052","volume":"100","author":"MX Li","year":"2022","unstructured":"Li MX, Li MY, Lei JX, Wu YZ, Li ZH, Chen LM, et al. Huangqin decoction ameliorates DSS-induced ulcerative colitis: role of gut microbiota and amino acid metabolism, mTOR pathway and intestinal epithelial barrier. Phytomedicine. 2022;100:154052.","journal-title":"Phytomedicine"},{"key":"1358_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153743","volume":"92","author":"YY Wei","year":"2021","unstructured":"Wei YY, Fan YM, Ga Y, Zhang YN, Han JC, Hao ZH. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1\/NF-\u03baB pathway. Phytomedicine. 2021;92:153743.","journal-title":"Phytomedicine"},{"issue":"1","key":"1358_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.apsb.2024.11.009","volume":"15","author":"W Jing","year":"2025","unstructured":"Jing W, Dong S, Xu Y, Liu J, Ren J, Liu X, et al. Gut microbiota-derived tryptophan metabolites regulated by Wuji Wan to attenuate colitis through AhR signaling activation. Acta Pharm Sin B. 2025;15(1):205\u201323.","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"1358_CR30","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s10620-012-2218-0","volume":"57","author":"T Iwasa","year":"2012","unstructured":"Iwasa T, Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. Feeding administration of Daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. Dig Dis Sci. 2012;57(10):2571\u20139.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1358_CR31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/jgh3.12410","volume":"4","author":"Y Kogure","year":"2020","unstructured":"Kogure Y, Kanda H, Wang S, Hao Y, Li J, Yamamoto S, et al. Daikenchuto attenuates visceral pain and suppresses eosinophil infiltration in inflammatory bowel disease in murine models. JGH Open. 2020;4(6):1146\u201354.","journal-title":"JGH Open"},{"key":"1358_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903459","volume":"13","author":"Z Shi","year":"2022","unstructured":"Shi Z, Takeuchi T, Nakanishi Y, Kato T, Beck K, Nagata R, et al. A Japanese herbal formula, Daikenchuto, alleviates experimental colitis by reshaping microbial profiles and enhancing Group 3 innate lymphoid cells. Front Immunol. 2022;13:903459.","journal-title":"Front Immunol"},{"key":"1358_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1298263","volume":"2017","author":"T Matsunaga","year":"2017","unstructured":"Matsunaga T, Hashimoto S, Yamamoto N, Kawasato R, Shirasawa T, Goto A, et al. Protective effect of Daikenchuto on dextran sulfate sodium-induced colitis in mice. Gastroenterol Res Pract. 2017;2017:1298263.","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"1358_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.fshw.2018.10.004","volume":"7","author":"V Rajendiran","year":"2018","unstructured":"Rajendiran V, Natarajan V, Devaraj SN. Anti-inflammatory activity of Alpinia officinarum hance on rat colon inflammation and tissue damage in DSS induced acute and chronic colitis models. Food Sci Hum Wellness. 2018;7(4):273\u201381.","journal-title":"Food Sci Hum Wellness"},{"issue":"2","key":"1358_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1124\/jpet.118.249615","volume":"366","author":"W Jing","year":"2018","unstructured":"Jing W, Safarpour Y, Zhang T, Guo P, Chen G, Wu X, et al. Berberine upregulates P-Glycoprotein in human caco-2 cells and in an experimental model of colitis in the rat via activation of Nrf2-dependent mechanisms. J Pharmacol Exp Ther. 2018;366(2):332\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"1358_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105358","volume":"164","author":"W Jing","year":"2021","unstructured":"Jing W, Dong S, Luo X, Liu J, Wei B, Du W, et al. Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. Pharmacol Res. 2021;164:105358.","journal-title":"Pharmacol Res"},{"key":"1358_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105767","volume":"171","author":"S Dong","year":"2021","unstructured":"Dong S, Zhu M, Wang K, Zhao X, Hu L, Jing W, et al. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharmacol Res. 2021;171:105767.","journal-title":"Pharmacol Res"},{"issue":"7","key":"1358_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41575-018-0003-z","volume":"15","author":"T Zuo","year":"2018","unstructured":"Zuo T, Kamm MA, Colombel JF, Ng SC. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):440\u201352.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1358_CR39","doi-asserted-by":"publisher","first-page":"1340442","DOI":"10.3389\/fimmu.2023.1340442","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Du C, Subramanian S, Turner L, Geng H, Bu HF, et al. Severe gut mucosal injury induces profound systemic inflammation and spleen-associated lymphoid organ response. Front Immunol. 2023;14:1340442.","journal-title":"Front Immunol"},{"issue":"7","key":"1358_CR40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/CM9.0000000000003542","volume":"138","author":"J Wan","year":"2025","unstructured":"Wan J, Zhou J, Wang Z, Liu D, Zhang H, Xie S, et al. Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years. Chin Med J (Engl). 2025;138(7):763\u201376.","journal-title":"Chin Med J (Engl)"},{"key":"1358_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/neq067","volume":"2011","author":"K Watanabe","year":"2011","unstructured":"Watanabe K, Matsuura K, Gao P, Hottenbacher L, Tokunaga H, Nishimura K, et al. Traditional Japanese Kampo medicine: clinical research between modernity and traditional medicine-the state of research and methodological suggestions for the future. Evid Based Complement Alternat Med. 2011;2011:513842.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1358_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00159","volume":"6","author":"T Kono","year":"2015","unstructured":"Kono T, Shimada M, Yamamoto M, Kaneko A, Oomiya Y, Kubota K, et al. Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto. Front Pharmacol. 2015;6:159.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1358_CR43","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1053\/j.gastro.2018.12.001","volume":"156","author":"S Paramsothy","year":"2019","unstructured":"Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019;156(5):1440-54.e2.","journal-title":"Gastroenterology"},{"issue":"10","key":"1358_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrgastro.2012.152","volume":"9","author":"C Manichanh","year":"2012","unstructured":"Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599\u2013608.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"1358_CR45","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/10408398.2011.619671","volume":"54","author":"R Ashraf","year":"2014","unstructured":"Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938\u201356.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"11","key":"1358_CR46","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/bph.13632","volume":"174","author":"D Curr\u00f2","year":"2017","unstructured":"Curr\u00f2 D, Ianiro G, Pecere S, Bibb\u00f2 S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol. 2017;174(11):1426\u201349.","journal-title":"Br J Pharmacol"},{"issue":"Pt 1","key":"1358_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.128592","volume":"257","author":"L Pan","year":"2024","unstructured":"Pan L, Ma M, Wang Y, Dai W, Fu T, Wang L, et al. Polyguluronate alleviates ulcerative colitis by targeting the gut commensal Lactobacillus murinus and its anti-inflammatory metabolites. Int J Biol Macromol. 2024;257(Pt 1):128592.","journal-title":"Int J Biol Macromol"},{"issue":"11","key":"1358_CR48","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1038\/s41396-018-0211-0","volume":"12","author":"XB Lin","year":"2018","unstructured":"Lin XB, Wang T, Stothard P, Corander J, Wang J, Baines JF, et al. The evolution of ecological facilitation within mixed-species biofilms in the mouse gastrointestinal tract. The ISME Journal. 2018;12(11):2770\u201384.","journal-title":"The ISME Journal"},{"issue":"1","key":"1358_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02127-z","volume":"21","author":"XY Li","year":"2021","unstructured":"Li XY, Li LX, Li Y, Zhou RC, Li B, Gu X, et al. Complete genome sequencing of Peyer\u2019s patches-derived Lactobacillus taiwanensis CLG01, a potential probiotic with antibacterial and immunomodulatory activity. BMC Microbiol. 2021;21(1):68.","journal-title":"BMC Microbiol"},{"key":"1358_CR50","doi-asserted-by":"crossref","unstructured":"Liu HY, Li S, Ogamune KJ, Yuan P, Shi X, Ennab W, et al. Probiotic Lactobacillus johnsonii reduces intestinal inflammation and rebalances splenic Treg\/Th17 responses in dextran sulfate sodium-induced colitis. Antioxidants. 2025;14(4):433","DOI":"10.3390\/antiox14040433"},{"key":"1358_CR51","doi-asserted-by":"crossref","unstructured":"Chen S, Niu X, Zhang Y, Wen J, Bao M, Li Y, et al. Butyrolactone-I from marine fungi alleviates intestinal barrier damage caused by DSS through regulating Lactobacillus johnsonii and its metabolites in the intestine of mice. J Nutr Biochem. 2025;135:109786.","DOI":"10.1016\/j.jnutbio.2024.109786"},{"issue":"4","key":"1358_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","volume":"17","author":"A Lavelle","year":"2020","unstructured":"Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"1358_CR53","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/gutjnl-2023-329969","volume":"73","author":"A Vich Vila","year":"2024","unstructured":"Vich Vila A, Zhang J, Liu M, Faber KN, Weersma RK. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases. Gut. 2024;73(11):1909\u201320.","journal-title":"Gut"},{"issue":"3","key":"1358_CR54","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s12016-020-08789-3","volume":"59","author":"L Pernomian","year":"2020","unstructured":"Pernomian L, Duarte-Silva M, de Barros Cardoso CR. The aryl hydrocarbon receptor (AHR) as a potential target for the control of intestinal inflammation: insights from an immune and bacteria sensor receptor. Clin Rev Allergy Immunol. 2020;59(3):382\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"1358_CR55","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nm.4102","volume":"22","author":"B Lamas","year":"2016","unstructured":"Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22(6):598\u2013605.","journal-title":"Nat Med"},{"key":"1358_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.739337","volume":"8","author":"S Xu","year":"2021","unstructured":"Xu S, Zhao M, Wang Q, Xu Z, Pan B, Xue Y, et al. Effectiveness of probiotics and prebiotics against acute liver injury: a meta-analysis. Front Med (Lausanne). 2021;8:739337.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1358_CR57","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41564-023-01363-5","volume":"8","author":"JX Han","year":"2023","unstructured":"Han JX, Tao ZH, Wang JL, Zhang L, Yu CY, Kang ZR, et al. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer. Nat Microbiol. 2023;8(5):919\u201333.","journal-title":"Nat Microbiol"},{"issue":"45","key":"1358_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2309032120","volume":"120","author":"K Yu","year":"2023","unstructured":"Yu K, Li Q, Sun X, Peng X, Tang Q, Chu H, et al. Bacterial indole-3-lactic acid affects epithelium-macrophage crosstalk to regulate intestinal homeostasis. Proc Natl Acad Sci U S A. 2023;120(45):e2309032120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1358_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104838","volume":"25","author":"N Seki","year":"2022","unstructured":"Seki N, Kimizuka T, Gondo M, Yamaguchi G, Sugiura Y, Akiyama M, et al. (D)-tryptophan suppresses enteric pathogen and pathobionts and prevents colitis by modulating microbial tryptophan metabolism. iScience. 2022;25(8):104838.","journal-title":"iScience"},{"issue":"2","key":"1358_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70007","volume":"4","author":"L Huang","year":"2025","unstructured":"Huang L, Wang P, Liu S, Deng G, Qi X, Sun G, et al. Gut microbiota-derived tryptophan metabolites improve total parenteral nutrition-associated infections by regulating Group 3 innate lymphoid cells. Imeta. 2025;4(2):e70007.","journal-title":"Imeta"},{"issue":"1","key":"1358_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/gastro\/goy052","volume":"7","author":"BO Schroeder","year":"2019","unstructured":"Schroeder BO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota. Gastroenterol Rep (Oxf). 2019;7(1):3\u201312.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"1","key":"1358_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrmicro3552","volume":"14","author":"GP Donaldson","year":"2015","unstructured":"Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2015;14(1):20\u201332.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"1358_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01031-19","volume":"10","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sperandio V. Indole signaling at the host-microbiota-pathogen interface. MBio. 2019;10(3):01031-19.","journal-title":"MBio"},{"key":"1358_CR64","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.biomaterials.2016.06.018","volume":"101","author":"M Zhang","year":"2016","unstructured":"Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321\u201340.","journal-title":"Biomaterials"},{"issue":"11","key":"1358_CR65","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1039\/D4FO00952E","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Zhang Y, Wang Q, Wang Y, Fan Y, Shang E, et al. 6-gingerol ameliorates ulcerative colitis by inhibiting ferroptosis based on the integrative analysis of plasma metabolomics and network pharmacology. Food Funct. 2024;15(11):6054\u201367.","journal-title":"Food Funct"},{"key":"1358_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jconrel.2020.04.032","volume":"323","author":"C Yang","year":"2020","unstructured":"Yang C, Zhang M, Lama S, Wang L, Merlin D. Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis. J Control Release. 2020;323:293\u2013310.","journal-title":"J Control Release"},{"issue":"9","key":"1358_CR67","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41401-020-00561-9","volume":"42","author":"JY Dong","year":"2021","unstructured":"Dong JY, Xia KJ, Liang W, Liu LL, Yang F, Fang XS, et al. Ginsenoside Rb1 alleviates colitis in mice via activation of endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 signaling pathway. Acta Pharmacol Sin. 2021;42(9):1461\u201371.","journal-title":"Acta Pharmacol Sin"},{"key":"1358_CR68","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.2147\/DDDT.S481769","volume":"18","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Xiong X, Cheng Z, Chen Z, Wu S, Yu Y, et al. Ginsenoside Rb1 alleviates DSS-Induced ulcerative colitis by protecting the intestinal barrier through the signal network of VDR, PPAR\u03b3 and NF-\u03baB. Drug Des Devel Ther. 2024;18:4825\u201338.","journal-title":"Drug Des Devel Ther"},{"key":"1358_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817600","volume":"13","author":"H Cheng","year":"2022","unstructured":"Cheng H, Liu J, Zhang D, Wang J, Tan Y, Feng W, et al. Ginsenoside Rg1 alleviates acute ulcerative colitis by modulating gut microbiota and microbial tryptophan metabolism. Front Immunol. 2022;13:817600.","journal-title":"Front Immunol"},{"key":"1358_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108133","volume":"100","author":"J Jin","year":"2021","unstructured":"Jin J, Zhong Y, Long J, Wu T, Jiang Q, Wang H, et al. Ginsenoside Rg1 relieves experimental colitis by regulating balanced differentiation of Tfh\/Treg cells. Int Immunopharmacol. 2021;100:108133.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1358_CR71","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jid.2017.09.035","volume":"138","author":"J Hiller","year":"2018","unstructured":"Hiller J, Hagl B, Effner R, Puel A, Schaller M, Mascher B, et al. STAT1 gain-of-function and dominant negative STAT3 mutations impair IL-17 and IL-22 immunity associated with CMC. J Invest Dermatol. 2018;138(3):711\u20134.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1358_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01934-w","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, et al. The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. 2024;9(1):221.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1358_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204.","journal-title":"Signal Transduct Target Ther"},{"key":"1358_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155779","volume":"132","author":"R Jia","year":"2024","unstructured":"Jia R, Zheng H, Li S, Chen W, Yang Y, Wu H, et al. QingChang-XiaoPi decoction ameliorates intestinal inflammation of ulcerative colitis by regulating the pathogenicity of Th17 cells. Phytomedicine. 2024;132:155779.","journal-title":"Phytomedicine"},{"key":"1358_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104712","volume":"211","author":"T Zhang","year":"2025","unstructured":"Zhang T, Xiaohan C. Unveiling the role of JAK2\/STAT3 signaling in chemoresistance of gynecological cancers: from mechanisms to therapeutic implications. Crit Rev Oncol Hematol. 2025;211:104712.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01358-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01358-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01358-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:02:01Z","timestamp":1773698521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01358-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01358-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7691083\/v1","asserted-by":"object"}]},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Experiment Administration Committee of Xi'an Jiaotong University Health Science Center in Shaanxi, People's Republic of China (NO. XJTUAE2022-1974).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We declare that the publisher has the authors' permission to publish the relevant contribution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Wanghui Jing is serving as a member of the Youth Editorial Board of Chinese Medicine. The author was not involved in the review or decision-making process for this manuscript. The authors declare no other conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}